How have NRXP shares performed in 2024?

NRx Pharmaceuticals' stock was trading at $46.00 at the beginning of 2024. Since then, NRXP stock has decreased by 93.3% and is now trading at $3.07. View the best growth stocks for 2024 here .

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 424,500 shares, a decline of 88.6% from the March 15th total of 3,710,000 shares. Based on an average trading volume of 159,600 shares, the short-interest ratio is presently 2.7 days. Approximately 6.7% of the shares of the company are short sold. View NRx Pharmaceuticals' Short Interest .

When is NRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our NRXP earnings forecast .

What ETF holds NRx Pharmaceuticals' stock?

AdvisorShares Psychedelics ETF holds 70,285 shares of NRXP stock, representing 4.74% of its portfolio.

When did NRx Pharmaceuticals' stock split?

NRx Pharmaceuticals shares reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has NRx Pharmaceuticals issued on next quarter's earnings?

NRx Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share (EPS) guidance of -0.400--0.400 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of -.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NRXP Stock Alerts

$3.07

+0.05 (+1.66%)

(As of 01:24 PM ET)

Compare

Today's Range: $3.00
▼
$3.25
50-Day Range: $3.02
▼
$70.06
52-Week Range: $2.21
▼
$12.00

Volume: 187,852 shs
Average Volume: 180,029 shs
Market Capitalization: $29.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get NRx Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

NRXP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRXP Stock News Headlines

April 18, 2024 | investorplace.com

Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?

April 18, 2024 | finance.yahoo.com

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 18, 2024 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

April 18, 2024 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

April 18, 2024 | prnewswire.com

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

April 17, 2024 | markets.businessinsider.com

NRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Flora

April 17, 2024 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

April 14, 2024 | msn.com

NRx Pharmaceuticals Advances in Breakthrough Bipolar Depression Treatment

April 8, 2024 | markets.businessinsider.com

NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study

April 8, 2024 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

April 3, 2024 | msn.com

New Brain Cap Lets People Play Video Games With Their Minds

April 3, 2024 | ca.news.yahoo.com

Woman, 23, diagnosed with cancer after thinking she was bloated with irritable bowel syndrome

April 3, 2024 | ca.news.yahoo.com

Rep. Raúl Grijalva announces cancer diagnosis

April 2, 2024 | ca.news.yahoo.com

Alberta creating 2 mental health and addictions organizations, including Crown corporation

April 2, 2024 | msn.com

There’s Nothing Wrong With Having Hooded Eyes

April 2, 2024 | msn.com

A dietitian explains how a 'diet break' can make it easier to lose weight and keep it off

April 2, 2024 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript

April 1, 2024 | msn.com

NRx Pharmaceuticals reports Q4 results

April 1, 2024 | prnewswire.com

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 28, 2024 | finanznachrichten.de

NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

March 28, 2024 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

March 28, 2024 | prnewswire.com

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

March 27, 2024 | msn.com

NRx Pharmaceuticals Set to Unveil Fourth Quarter and Full Year 2023 Financial Results

March 27, 2024 | finance.yahoo.com

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

See More Headlines

Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NRXP
CUSIP: N/A
CIK: 1719406
Web: www.bigrockpartners.com
Phone: (484) 254-6134
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,150,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -202.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.36
Quick Ratio: 0.36

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.38) per share
Price / Book: -2.19

Miscellaneous

Outstanding Shares: 9,570,000
Free Float: 7,555,000
Market Cap: $28.90 million
Optionable: Optionable
Beta: 1.02

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Jonathan C. Javitt M.D. (Age 67)
M.P.H., Co-Founder, Chief Scientist Officer & Chairman
Comp: $873.7k
Mr. Stephen H. Willard Esq. (Age 63)
Acting Corporate Secretary, CEO & Director
Comp: $501.19k
Dr. Riccardo Panicucci Ph.D. (Age 62)
Chief Technology Officer
Comp: $240k
Dr. Seth L. Van Voorhees Ph.D. (Age 63)
Treasurer
Comp: $399.96k
Mr. Richard Clavano Narido (Age 46)
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Suzanne Messere
Investor Relations
Dr. Philip T. Lavin Ph.D. (Age 77)
Chief Methodologist
Dr. Dennis K. McBride Ph.D.
Chief Strategy Officer & Senior Scientist
Mr. Matthew Patrick Duffy (Age 61)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed in 2024?: NRx Pharmaceuticals' stock was trading at $46.00 at the beginning of 2024. Since then, NRXP stock has decreased by 93.3% and is now trading at $3.07.
View the best growth stocks for 2024 here.
Are investors shorting NRx Pharmaceuticals?: NRx Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 424,500 shares, a decline of 88.6% from the March 15th total of 3,710,000 shares. Based on an average trading volume of 159,600 shares, the short-interest ratio is presently 2.7 days. Approximately 6.7% of the shares of the company are short sold.
View NRx Pharmaceuticals' Short Interest.
When is NRx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our NRXP earnings forecast.
What ETF holds NRx Pharmaceuticals' stock?: AdvisorShares Psychedelics ETF holds 70,285 shares of NRXP stock, representing 4.74% of its portfolio.

When did NRx Pharmaceuticals' stock split?: NRx Pharmaceuticals shares reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What guidance has NRx Pharmaceuticals issued on next quarter's earnings?: NRx Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share (EPS) guidance of -0.400--0.400 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of -.
How do I buy shares of NRx Pharmaceuticals?: Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRXP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

NRXP Stock Price History

NRXP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NRXP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info